Literature DB >> 6890893

Noninvasive glucose monitoring of the aqueous humor of the eye: Part II. Animal studies and the scleral lens.

W F March, B Rabinovitch, R L Adams.   

Abstract

We have discussed the nature of a scleral lens that will allow us to follow changes in aqueous humor glucose levels in animals by a method based on optical rotation and a technique described in an earlier paper. We have shown how this lens can be micro-miniaturized and can be used in humans as a non-invasive glucose monitor. We have described preliminary experiments designed to show the correlation between the blood glucose assay (BGA) and the aqueous humor glucose concentration as determined by chemical assay (AGA) and by optical rotation determination (ARD). The last mentioned has been obtained by paracentesis directly into a microcell used in conjunction with instrumentation capable of measuring optical rotations as low as 0.0013 degrees (4.5") corresponding to 20 mg/dl glucose with a sensitivity of 0.0001 degrees (0.36"). The variability among normal rabbits as a function of individuality and diurnal changes is described, and the correlation between AGA and ARD shown to be essentially 1.0. Such rabbits are examined when undergoing very rapid decreases in BGA (insulin treatment) or very rapid increases in BGA (bolus of glucose). The AGA and ARD are shown to lag behind the BGA, and this is discussed in terms of the rate of change of BGA with respect to time and its concomitant change in AGA/ARD as well as a simple procedure that would materially reduce this lag.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6890893     DOI: 10.2337/diacare.5.3.259

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

1.  In vivo glucose monitoring using dual-wavelength polarimetry to overcome corneal birefringence in the presence of motion.

Authors:  Casey W Pirnstill; Bilal H Malik; Vincent C Gresham; Gerard L Coté
Journal:  Diabetes Technol Ther       Date:  2012-06-12       Impact factor: 6.118

2.  Minimally invasive, direct, real time measurement of drug concentration in the anterior eye.

Authors:  J Miller; W S Wilson; C G Wilson; D Uttamchandani
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

Review 3.  Noninvasive diagnostic devices for diabetes through measuring tear glucose.

Authors:  Jin Zhang; William Hodge; Cindy Hutnick; Xianbin Wang
Journal:  J Diabetes Sci Technol       Date:  2011-01-01

Review 4.  Paradigm Shifts in Ophthalmic Diagnostics.

Authors:  J Sebag; Alfredo A Sadun; Eric A Pierce
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

5.  Corneal birefringence measured by spectrally resolved Mueller matrix ellipsometry and implications for non-invasive glucose monitoring.

Authors:  Peter Westphal; Johannes-Maria Kaltenbach; Kai Wicker
Journal:  Biomed Opt Express       Date:  2016-03-07       Impact factor: 3.732

6.  Assessment of subcutaneous glucose concentration: validation of the wick technique as a reference for implanted electrochemical sensors in normal and diabetic dogs.

Authors:  U Fischer; R Ertle; P Abel; K Rebrin; E Brunstein; H Hahn von Dorsche; E J Freyse
Journal:  Diabetologia       Date:  1987-12       Impact factor: 10.122

7.  Real-time, closed-loop dual-wavelength optical polarimetry for glucose monitoring.

Authors:  Bilal H Malik; Gerard L Coté
Journal:  J Biomed Opt       Date:  2010 Jan-Feb       Impact factor: 3.170

8.  Noninvasive polarimetric-based glucose monitoring: an in vivo study.

Authors:  Georgeanne Purvinis; Brent D Cameron; Douglas M Altrogge
Journal:  J Diabetes Sci Technol       Date:  2011-03-01

Review 9.  Progress toward an in vivo surface-enhanced Raman spectroscopy glucose sensor.

Authors:  Olga Lyandres; Jonathan M Yuen; Nilam C Shah; Richard P VanDuyne; Joseph T Walsh; Matthew R Glucksberg
Journal:  Diabetes Technol Ther       Date:  2008-08       Impact factor: 6.118

10.  Characterizing dual wavelength polarimetry through the eye for monitoring glucose.

Authors:  Bilal H Malik; Gerard L Coté
Journal:  Biomed Opt Express       Date:  2010-10-28       Impact factor: 3.732

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.